Skip to content
2000
Volume 11, Issue 4
  • ISSN: 1871-5222
  • E-ISSN: 1875-6115

Abstract

Natural estrogens such as 17β-estradiol are endogenous vasodilators and have been implicated in the gender differences of hypertension. These hormones activate estrogen receptors ERα and ERβ, which mediate part of estrogendependent vasodilation. In addition, a novel G protein-coupled estrogen-binding receptor termed GPER/GPR30 has been identified that is expressed in the cardiovascular system. Using knock-out animals or drugs selectively targeting GPER/GPR30, a significant role for this receptor as a mediator of acute estrogen-dependent vasodilation involving nitric oxide (NO) and blood pressure-lowering activity has been demonstrated. The accumulating evidence that GPER/GPR30 is responsible for control of vascular tone indicates that this receptor may represent a novel drug target for pharmacologic treatment of hypertension in postmenopausal women and possibly also men.

Loading

Article metrics loading...

/content/journals/iemamc/10.2174/1871522211108040255
2011-12-01
2025-09-17
Loading full text...

Full text loading...

/content/journals/iemamc/10.2174/1871522211108040255
Loading

  • Article Type:
    Research Article
Keyword(s): Blood pressure; endothelium; hormone therapy; hypertension; menopause; nitric oxide; vasodilation
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test